# CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be a) a guide for reporting for authors of RCTs, b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (nonpharmacologic treatment) items. Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red \*.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED). Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF \_AND\_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and

Mobile Health Interventions J Med Internet Res 2011;13(4):e126 URL: <u>http://www.jmir.org/2011/4/e126/</u> doi: 10.2196/jmir.1923 PMID: 22209829

\* Required

Your name \*

First Last

Tahereh Najafi Ghezeljeh

Primary Affiliation (short), City, Country \* University of Toronto, Toronto, Canada

Tehran

Your e-mail address \* abc@gmail.com

najafi.t@iums.ac.ir

Title of your manuscript \* Provide the (draft) title of your manuscript.

Effect of a Smartphone-Based App on the Quality of Life of Patients With Heart Failure: Randomized Controlled Trial

#### Name of your App/Software/Intervention \*

If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

My Smart Heart

#### Evaluated Version (if any)

e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

Your answer

#### Language(s) \*

What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

Persian

#### URL of your Intervention Website or App

e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

Your answer

URL of an image/screenshot (optional)

Your answer

# Accessibility \*

Can an enduser access the intervention presently?

#### access is free and open

access only for special usergroups, not open

access is open to everyone, but requires payment/subscription/in-app purchases

) app/intervention no longer accessible

) Other:

#### Primary Medical Indication/Disease/Condition \*

e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

Cardiovascular disorders

#### Primary Outcomes measured in trial \*


comma-separated list of primary outcomes reported in the trial

Quality of life

#### Secondary/other outcomes

Are there any other outcomes the intervention is expected to affect?

Your answer



Approx. Percentage of Users (starters) still using the app as recommended after 3 months \*

$\bigcirc$	unknown / not evaluated

- 0-10%
- 11-20%
- 21-30%
- 31-40%
- 41-50%
- 51-60%
- 61-70%
- 71%-80%
- 81-90%
- 91-100%
- Other:

:

Overall, was the app/intervention effective? *
• yes: all primary outcomes were significantly better in intervention group vs control
O partly: SOME primary outcomes were significantly better in intervention group vs control
O no statistically significant difference between control and intervention
O potentially harmful: control was significantly better than intervention in one or more outcomes
inconclusive: more research is needed
O Other:
Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form)
O not submitted yet - in early draft status
not submitted yet - in late draft status, just before submission

- submitted to a journal but not reviewed yet
- submitted to a journal and after receiving initial reviewer comments
- submitted to a journal and accepted, but not published yet
  - ) published
  - ) Other:


#### Journal \*

If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- ) not submitted yet / unclear where I will submit this
- Journal of Medical Internet Research (JMIR)
- JMIR mHealth and UHealth



- ) JMIR Mental Health
- JMIR Public Health
- JMIR Formative Research
- Other JMIR sister journal
- Other: JMIR Nursing



tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

) no ms number (yet) / not (yet) submitted to / published in JMIR

Other: 20747

#### TITLE AND ABSTRACT

#### 1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? *	
I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason un "other")	der
() yes	
O Other:	

#### 1a-i) Identify the mode of delivery in the title


Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					C	Clear selection

#### Does your paper address subitem 1a-i? \*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

# Effect of a Smartphone-Based App on the Quality of Life of Patients With Heart Failure: Randomized Controlled Trial




#### Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

#### Your answer

#### 1a-iii) Primary condition or target group in the title

Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial



#### Does your paper address subitem 1a-iii? \*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

# Effect of a Smartphone-Based App on the Quality of Life of Patients With Heart Failure: Randomized Controlled Trial

# 1b) ABSTRACT: Structured summary of trial design, methods, results, and


#### conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

# 1b-i) Key features/functionalities/components of the intervention and

#### comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



#### Does your paper address subitem 1b-i? \*

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This randomized controlled clinical trial with a control group was conducted from June to October 2018 in an urban hospital. In this study, 120 patients with heart failure hospitalized in cardiac care units were randomly allocated to control and intervention groups. Besides routine care, patients in the intervention group received a smartphone-based app and used it every day for 3 months. Both the groups completed the Minnesota Living with Heart Failure Questionnaire before entering the study and at 3 months after entering the study. Data were analyzed using the SPSS software V.16.

# 1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	۲	0	0	0	0	essential
					C	Clear selection


#### Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

# 1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the

researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



#### Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

#### in an urban hospital

#### 1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					(	Clear selection

#### Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

#### every day for 3 months

#### 1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)  $1 \quad 2 \quad 3 \quad 4 \quad 5$ 

subitem not at all important	0	0	0	0	۲	essential
					1	Clear selection

#### Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The groups showed statistically significant differences in the mean scores of quality of life and its dimensions after the intervention, indicating a better quality of life in the intervention group

INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale

#### 2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)  $1 \quad 2 \quad 3 \quad 4 \quad 5$ 

subitem not at all important	0	0	0	0	۲	essential
					(	Clear selection

#### Does your paper address subitem 2a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Use of apps or software on the smartphone can facilitate monitoring of patients' health through educational messages, audio files, and video clips. Smartphone-based apps have the potential to collect real-time data and graphically draw data for further interactions

#### 2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					(	Clear selection

#### Does your paper address subitem 2a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

In general, although some apps have been developed for patient care, only few studies have examined their effectiveness. The effectiveness of smartphone-based apps for the management of some diseases and conditions have already been evaluated, such as in patients with chronic pain [22], for the diagnosis and notification of acute pesticide poisonings [23], and in patients undergoing heart valve replacement [24].

2b) In INTRODUCTION: Specific objectives or hypotheses

Does your paper address CONSORT subitem 2b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The aim of this study was to design and validate a smartphone app called "My Smart Heart" [25] and to investigate its effect on the QoL of patients with HF.

#### **METHODS**

3a) Description of trial design (such as parallel, factorial) including allocation ratio

#### Does your paper address CONSORT subitem 3a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

the ratio of 1:1

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

#### 3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					C	Clear selection

•

#### Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

#### 4a) Eligibility criteria for participants

#### Does your paper address CONSORT subitem 4a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

age of 18-65 years, being literate, class II or III of HF according to the New York Heart Association classification, patients admitted to the hospital due to exacerbation of HF, having a smartphone or a tablet with the Android operating system, and ability to use a smartphone and the app.

# 4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

1	2	3	4	5	
0	0	0	0	۲	essential
				C	Clear selection
	-	_			$\circ$ $\circ$ $\circ$ $\circ$


#### Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

#### ability to use a smartphone and the app

#### 4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely webbased trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.



#### Does your paper address subitem 4a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

#### both online and offline

#### 4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					C	Clear selection

#### Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


willing patients signed the letter of consent before the study. This study adhered to the basic ethics principles and the tenets of the Declaration of Helsinki.

4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

cardiac care units of Mashhad Medical Center



#### Does your paper address subitem 4b-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

the same questionnaire was sent to the patients via the smartphone's virtual social network to be filled out.

#### 4b-ii) Report how institutional affiliations are displayed

Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention.(Not a required item – describe only if this may bias results)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					C	Clear selection

#### Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study was a randomized clinical trial (pretest and posttest with a control group design), which was conducted in 2018 in cardiac care units of Mashhad Medical Center, Iran. After obtaining approval from the ethics committee affiliated with the Iran University of Medical Sciences

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

5-i) Mention names, credential, affiliations of the developers, sponsors, and

#### owners


Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					(	Clear selection

#### Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Patients in the intervention group received the smartphone-based app besides routine care. It was installed on their Android phones, and the patients were taught how to use the program via a 30-minute face-to-face session. The app brochure was also provided to the patients. The method of measuring vital signs, monitoring symptoms, and recording them in the app were taught to patients via the educational content of the app. Every week for 6 consecutive weeks and then every month for about 2 months, notifications were sent to the patients to remind them to use the app. Patients were asked to enter their daily vital signs, symptoms, and weight in the app, which provided the opportunity for health care providers to telemonitor the changes in the data in the text and graph format. In addition, patients could evaluate their daily conditions and its changes by visualizing the recorded data in the shape of a graph. Further, the daily use of the app by the patients was evaluated by the management panel on the internet and encouragements for the use of the app were provided, as needed. Patients and researchers could interact with each other depending on the patients' needs. During the app usage period (3 months), the patients were supported in terms of how to use the program. To provide support, the researcher's telephone number was provided to the patients for contact purposes, if needed. The patients in the control group received routine care, which included the provision of a brochure and the method of taking medicines and referral to the doctor at a clinic 2 weeks later. Moreover, the patients in the control group were provided with the smartphonebased app after data collection.



#### Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

An Android-based smartphone app was developed and evaluated [25]. This interactive app (Figure 2) can be used both online and offline. The main characteristics of this app are profiles, reminders, educational content, educational videos, daily messages, pharmacy guides, frequently asked questions, daily recording of physical and psychological symptoms, and vital signs and sending alerts as needed. This app was evaluated by patients, health care providers, nurses, physicians, and programmers, thereby indicating its simple and convenient use and consistency with the principles of the American Heart Failure Association and the Institute of Health Information Technology [25]. This app has the following features: (1) informing: information about disease, symptoms, symptom management, treatment, and care in various formats (text, photos, and videos); (2) instruction: provision of instructions for the user of the app; (3) recording: ability to record user's information under the subsets of collecting information, sharing information with the researcher, evaluating information, and intervening, as needed; (4) displaying: displaying data regarding symptoms, vital signs, and weights graphically and textually, as well as the ability to extract the PDF and XML formats; (5) guiding: provision of guidance based on the data given by the user and provision of appropriate advice through communication with the researcher; (6) reminder or alert: reminding the user regarding the time of taking medicines, performing tests, and other requirements; and (7) interaction: bilateral interaction between the researcher and patient [25]. This app was provided to patients to use for 3 months.

#### 5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).


	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					C	Clear selection



#### Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

An Android-based smartphone app was developed and evaluated [25]. This interactive app (Figure 2) can be used both online and offline. The main characteristics of this app are profiles, reminders, educational content, educational videos, daily messages, pharmacy guides, frequently asked questions, daily recording of physical and psychological symptoms, and vital signs and sending alerts as needed. This app was evaluated by patients, health care providers, nurses, physicians, and programmers, thereby indicating its simple and convenient use and consistency with the principles of the American Heart Failure Association and the Institute of Health Information Technology [25]. This app has the following features: (1) informing: information about disease, symptoms, symptom management, treatment, and care in various formats (text, photos, and videos); (2) instruction: provision of instructions for the user of the app; (3) recording: ability to record user's information under the subsets of collecting information, sharing information with the researcher, evaluating information, and intervening, as needed; (4) displaying: displaying data regarding symptoms, vital signs, and weights graphically and textually, as well as the ability to extract the PDF and XML formats; (5) guiding: provision of guidance based on the data given by the user and provision of appropriate advice through communication with the researcher; (6) reminder or alert: reminding the user regarding the time of taking medicines, performing tests, and other requirements; and (7) interaction: bilateral interaction between the researcher and patient [25]. This app was provided to patients to use for 3 months.



#### Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

An Android-based smartphone app was developed and evaluated [25]. This interactive app (Figure 2) can be used both online and offline. The main characteristics of this app are profiles, reminders, educational content, educational videos, daily messages, pharmacy guides, frequently asked questions, daily recording of physical and psychological symptoms, and vital signs and sending alerts as needed. This app was evaluated by patients, health care providers, nurses, physicians, and programmers, thereby indicating its simple and convenient use and consistency with the principles of the American Heart Failure Association and the Institute of Health Information Technology [25]. This app has the following features: (1) informing: information about disease, symptoms, symptom management, treatment, and care in various formats (text, photos, and videos); (2) instruction: provision of instructions for the user of the app; (3) recording: ability to record user's information under the subsets of collecting information, sharing information with the researcher, evaluating information, and intervening, as needed; (4) displaying: displaying data regarding symptoms, vital signs, and weights graphically and textually, as well as the ability to extract the PDF and XML formats; (5) guiding: provision of guidance based on the data given by the user and provision of appropriate advice through communication with the researcher; (6) reminder or alert: reminding the user regarding the time of taking medicines, performing tests, and other requirements; and (7) interaction: bilateral interaction between the researcher and patient [25]. This app was provided to patients to use for 3 months.

5-v) Ensure replicability by p	ublishin	g the so	ource co	de, and	/or prov	viding
screenshots/screen-capture	video, a	and/or p	roviding	g flowch	arts of	the algorithms
used						
Ensure replicability by publishing the and/or providing flowcharts of the alg principle be able to replicate the stud	gorithms (	used. Repl	icability (i.	e., other re		•
	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						Clear selection

#### Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

#### 5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, <u>webcitation.org</u>, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					(	Clear selection

#### Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

#### 5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					C	Clear selection

#### Does your paper address subitem 5-vii? \*


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

It was installed on their Android phones, and the patients were taught how to use the program via a 30-minute face-to-face session. The app brochure was also provided to the patients.

# 5-viii) Mode of delivery, features/functionalities/components of the intervention

#### and comparator, and the theoretical framework


Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].



#### Does your paper address subitem 5-viii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Patients in the intervention group received the smartphone-based app besides routine care. It was installed on their Android phones, and the patients were taught how to use the program via a 30-minute face-to-face session. The app brochure was also provided to the patients. The method of measuring vital signs, monitoring symptoms, and recording them in the app were taught to patients via the educational content of the app. Every week for 6 consecutive weeks and then every month for about 2 months, notifications were sent to the patients to remind them to use the app. Patients were asked to enter their daily vital signs, symptoms, and weight in the app, which provided the opportunity for health care providers to telemonitor the changes in the data in the text and graph format. In addition, patients could evaluate their daily conditions and its changes by visualizing the recorded data in the shape of a graph. Further, the daily use of the app by the patients was evaluated by the management panel on the internet and encouragements for the use of the app were provided, as needed. Patients and researchers could interact with each other depending on the patients' needs. During the app usage period (3 months), the patients were supported in terms of how to use the program. To provide support, the researcher's telephone number was provided to the patients for contact purposes, if needed. The patients in the control group received routine care, which included the provision of a brochure and the method of taking medicines and referral to the doctor at a clinic 2 weeks later. Moreover, the patients in the control group were provided with the smartphonebased app after data collection.




#### Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Patients in the intervention group received the smartphone-based app besides routine care. It was installed on their Android phones, and the patients were taught how to use the program via a 30-minute face-to-face session. The app brochure was also provided to the patients. The method of measuring vital signs, monitoring symptoms, and recording them in the app were taught to patients via the educational content of the app. Every week for 6 consecutive weeks and then every month for about 2 months, notifications were sent to the patients to remind them to use the app. Patients were asked to enter their daily vital signs, symptoms, and weight in the app, which provided the opportunity for health care providers to telemonitor the changes in the data in the text and graph format. In addition, patients could evaluate their daily conditions and its changes by visualizing the recorded data in the shape of a graph. Further, the daily use of the app by the patients was evaluated by the management panel on the internet and encouragements for the use of the app were provided, as needed. Patients and researchers could interact with each other depending on the patients' needs. During the app usage period (3 months), the patients were supported in terms of how to use the program. To provide support, the researcher's telephone number was provided to the patients for contact purposes, if needed. The patients in the control group received routine care, which included the provision of a brochure and the method of taking medicines and referral to the doctor at a clinic 2 weeks later. Moreover, the patients in the control group were provided with the smartphonebased app after data collection.

#### 5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).



#### Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

#### 5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).



#### Does your paper address subitem 5-xi? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Every week for 6 consecutive weeks and then every month for about 2 months, notifications were sent to the patients to remind them to use the app.

# 5-xii) Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 - generalizability.

#### Does your paper address subitem 5-xii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

#### Does your paper address CONSORT subitem 6a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Data were collected from the patients' medical records and through interviews using the demographic data form, health information form, and Minnesota Living with Heart Failure Questionnaire (MLHFQ).

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were

designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						Clear selection

Does your paper address subitem 6a-i?

Copy and paste relevant sections from manuscript text

N/A

Describe whether and how "use" (incl (logins, logfile analysis, etc.). Use/ad reported in any ehealth trial.	-	-	-	•		
	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
						Clear selection
Does your paper address sub						
Copy and paste relevant sections from	n manuso	cript text				
N/A						
N/A 6a-iii) Describe whether, how was obtained	v, and w	/hen qua	alitative	feedbad	ck from	participants
6a-iii) Describe whether, hov	litative fe	edback fro				
6a-iii) Describe whether, hov was obtained Describe whether, how, and when qua	litative fe	edback fro				
6a-iii) Describe whether, hov was obtained Describe whether, how, and when qua	litative fe ocus grou	edback fro ps).	om particij	pants was	obtained	
6a-iii) Describe whether, how was obtained Describe whether, how, and when qua emails, feedback forms, interviews, fo	litative fe ocus grou	edback fro ps).	om particij	pants was	obtained 5	(e.g., through
6a-iii) Describe whether, how was obtained Describe whether, how, and when qua emails, feedback forms, interviews, fo	litative fe ocus grou 1 O	edback fro ps). 2 O a-iii?	om particij	pants was	obtained 5	(e.g., through essential

6b) Any changes to trial outcomes after the trial commenced, with reasons

#### Does your paper address CONSORT subitem 6b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

#### 7a) How sample size was determined NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

## 7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size

Describe whether and how expected attrition was taken into account when calculating the sample size.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					C	Clear selection

#### Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

To estimate the sample size at 95% confidence interval, 80% power, assuming that the effect size of the intervention on the QoL in the intervention group compared to the control group would be at least d=10.5 and SD=18 [26] and with 25% possibility of sample dropout, the sample size was considered as 60 people in each group

7b) When applicable, explanation of any interim analyses and stopping guidelines

#### Does your paper address CONSORT subitem 7b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

#### Does your paper address CONSORT subitem 8a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The sequential sampling method was used. The randomized block method with the ratio of 1:1 and no permutation was used to assign the patients to the groups. Different modes of assignments to the groups were written on 4 cards and placed in opaque envelopes. Next, the envelopes were placed in a box. A research collaborator who was unaware of the assignment process took the envelopes from the box and determined each patient's place in the groups. This process was continued until the desired sample size was achieved

8b) Type of randomisation; details of any restriction (such as blocking and block size)

#### Does your paper address CONSORT subitem 8b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The sequential sampling method was used. The randomized block method with the ratio of 1:1 and no permutation was used to assign the patients to the groups. Different modes of assignments to the groups were written on 4 cards and placed in opaque envelopes. Next, the envelopes were placed in a box. A research collaborator who was unaware of the assignment process took the envelopes from the box and determined each patient's place in the groups. This process was continued until the desired sample size was achieved

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

#### Does your paper address CONSORT subitem 9? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The sequential sampling method was used. The randomized block method with the ratio of 1:1 and no permutation was used to assign the patients to the groups. Different modes of assignments to the groups were written on 4 cards and placed in opaque envelopes. Next, the envelopes were placed in a box. A research collaborator who was unaware of the assignment process took the envelopes from the box and determined each patient's place in the groups. This process was continued until the desired sample size was achieved

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

#### Does your paper address CONSORT subitem 10? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The sequential sampling method was used. The randomized block method with the ratio of 1:1 and no permutation was used to assign the patients to the groups. Different modes of assignments to the groups were written on 4 cards and placed in opaque envelopes. Next, the envelopes were placed in a box. A research collaborator who was unaware of the assignment process took the envelopes from the box and determined each patient's place in the groups. This process was continued until the desired sample size was achieved

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					C	Clear selection


#### Does your paper address subitem 11a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

It should be noted that due to the nature of the intervention, there was no possibility of blinding the subjects.

11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".



#### Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

It should be noted that due to the nature of the intervention, there was no possibility of blinding the subjects.

## 11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

#### Does your paper address CONSORT subitem 11b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

## N/A

## 12a) Statistical methods used to compare groups for primary and secondary

#### outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

#### Does your paper address CONSORT subitem 12a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The two-sided t test was used to compare the quantitative variables. The chisquare and Fisher exact tests were used for comparing the qualitative variables between the 2 groups. The two-factor analysis of variance was used for determining the effect of demographic and health information on the QoL in order to investigate the effects of 2 factors (intervention and demographic and health information) on the dependent variable. The repeated measure analysis of variance test was used to determine the effect of the intervention over time.

## 12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					(	Clear selection

#### Does your paper address subitem 12a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

#### Does your paper address CONSORT subitem 12b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The two-sided t test was used to compare the quantitative variables. The chisquare and Fisher exact tests were used for comparing the qualitative variables between the 2 groups. The two-factor analysis of variance was used for determining the effect of demographic and health information on the QoL in order to investigate the effects of 2 factors (intervention and demographic and health information) on the dependent variable. The repeated measure analysis of variance test was used to determine the effect of the intervention over time.

# X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

X26-i) Comment on ethics committee approval									
	1	2	3	4	5				
subitem not at all important	0	0	0	0	۲	essential			
					C	Clear selection			

## Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

obtaining approval from the ethics committee affiliated with the Iran University of Medical Sciences (code: 1396.9411449003) and registration on the website of clinical trials (code: IRCT2017061934647N1),

#### x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					(	Clear selection

## Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

willing patients signed the letter of consent before the study. This study adhered to the basic ethics principles and the tenets of the Declaration of Helsinki.

## X26-iii) Safety and security procedures

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					C	Clear selection

#### Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

## RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

#### Does your paper address CONSORT subitem 13a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

before the study, the mean score of QoL in the intervention and control groups were 42.91 (15.62) and 47.42 (16.38), respectively. The independent two-sided t test showed that the groups had no statistically significant differences before the study in any of the dimensions (P=.14). At 3 months after the intervention (Table 2), the mean scores of QoL in the intervention and control groups were 26.03 (9.67) and 50.13 (15.54), respectively. The groups had statistically significant differences in the QoL after the intervention, indicating a better QoL in the intervention group (P<.001). According to the results, the effect size of the intervention was high. The mean scores of QoL after the intervention in the intervention group in all domains were less than those in the control group, indicating better QoL in the intervention group compared to that in the control group (P<.001). The effect size of the intervention was high. In the intervention group, the reduced scores indicated improved QoL in all the domains compared to that in the control group. In the intervention group, the total and all the domain mean scores of QoL before and after the intervention had a statistically significant difference, indicating an improved QoL after the use of the app (P<.001). In the control group, the total mean score of QoL before and after the intervention showed a statistically significant difference (P=.001). The mean score of QoL in the control group in all dimensions before and after the intervention showed a statistically significant difference, indicating a reduced QoL in all domains over 3 months.

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is


## shown in a CONSORT flow diagram) \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

In this study, data collected from 111 patients were used for the analysis. (Figure 1).

## 13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.



#### Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

(Figure 1)

14a) Dates defining the periods of recruitment and follow-up

## Does your paper address CONSORT subitem 14a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

## which was conducted in 2018

14a-i) Indicate if critical "secu	ılar eve	nts" fell	into the	study p	period			
Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"								
	1	2	3	4	5			
subitem not at all important	0	0	0	0	$\bigcirc$	essential		

#### Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

**Clear selection** 

N/A

## 14b) Why the trial ended or was stopped (early)

#### Does your paper address CONSORT subitem 14b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

## 15) A table showing baseline demographic and clinical characteristics for each

#### group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

## Does your paper address CONSORT subitem 15? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

#### Table 1

## 15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					C	Clear selection

#### Does your paper address subitem 15-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

## 16-i) Report multiple "denominators" and provide definitions

Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					C	Clear selection

#### Does your paper address subitem 16-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

### Tables 2-4

## 16-ii) Primary analysis should be intent-to-treat Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i). 1 2 3 4 5 subitem not at all important O O O O O essential

#### Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

#### Does your paper address CONSORT subitem 17a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

#### Table 2

17a-i) Presentation of process outcomes such as metrics of use and intensity of

#### use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

#### Does your paper address CONSORT subitem 17b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18?\*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

tables 3-4

#### 18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					C	Clear selection

H

#### Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

## 19) All important harms or unintended effects in each group

(for specific guidance see CONSORT for harms)

## Does your paper address CONSORT subitem 19?\*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

#### 19-i) Include privacy breaches, technical problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

## 19-ii) Include qualitative feedback from participants or observations from

#### staff/researchers

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

## DISCUSSION

## 22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)						
Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).						
	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					C	Clear selection

Does your paper address subitem 22-i?\*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

In this study, according to the findings, changes in the QoL score and its dimensions in the intervention group were more than those of the control group, and the effect size of the intervention was high. Therefore, use of a smartphone-based app increased the QoL and its dimensions in patients with HF.



#### Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The smartphone-based app used in our study provides a novel telemonitoring and education method for patients with HF. This study was conducted on those patients who were able to communicate and were literate, with an ejection fraction of less than 45%. For generalizability, similar studies should be conducted in illiterate patients. In this study, the effect of the intervention was studied after 3 months, but the long-term effects of the intervention need to be further researched. In this study, the mediator effects of knowledge and self-care improvement were not evaluated, and therefore, these should be investigated in future studies. Within 3 months of the study process, some medication errors were identified. Therefore, studies should be conducted to influence the use of software in improving patient safety and reducing medication errors.

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

#### 20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.



#### Does your paper address subitem 20-i? \*


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The smartphone-based app used in our study provides a novel telemonitoring and education method for patients with HF. This study was conducted on those patients who were able to communicate and were literate, with an ejection fraction of less than 45%. For generalizability, similar studies should be conducted in illiterate patients. In this study, the effect of the intervention was studied after 3 months, but the long-term effects of the intervention need to be further researched. In this study, the mediator effects of knowledge and self-care improvement were not evaluated, and therefore, these should be investigated in future studies. Within 3 months of the study process, some medication errors were identified. Therefore, studies should be conducted to influence the use of software in improving patient safety and reducing medication errors.

**21)** Generalisability (external validity, applicability) of the trial findings NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

#### 21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations



#### Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The smartphone-based app used in our study provides a novel telemonitoring and education method for patients with HF. This study was conducted on those patients who were able to communicate and were literate, with an ejection fraction of less than 45%. For generalizability, similar studies should be conducted in illiterate patients. In this study, the effect of the intervention was studied after 3 months, but the long-term effects of the intervention need to be further researched. In this study, the mediator effects of knowledge and self-care improvement were not evaluated, and therefore, these should be investigated in future studies. Within 3 months of the study process, some medication errors were identified. Therefore, studies should be conducted to influence the use of software in improving patient safety and reducing medication errors.

## 21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

2

3

subitem not at all important OOO

1

**Clear selection** 

essential

5

( )

#### Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

#### **OTHER INFORMATION**

#### 23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

IRCT2017061934647N1

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? \*

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A

25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


The Iran University of Medical Sciences supported this study

.

## X27) Conflicts of Interest (not a CONSORT item)

#### X27-i) State the relation of the study team towards the system being evaluated

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.



#### Does your paper address subitem X27-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

None declared.

## About the CONSORT EHEALTH checklist

As a result of using this checklist, did you make changes in your manuscript? \*

- yes, major changes
- yes, minor changes
- 🔵 no

What were the most important changes you made as a result of using this checklist?

Your answer

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript \*

1 hour

As a result of using this checklist, do you think your manuscript h	nas improved? *
O yes	
o no	
O Other:	
Would you like to become involved in the CONSORT EHEALTH gr This would involve for example becoming involved in participating in a workshop ar "Explanation and Elaboration" document	•
<ul><li>● yes</li></ul>	
O no	
O Other:	
	Clear selection

Any other comments or questions on CONSORT EHEALTH

Your answer

#### STOP - Save this form as PDF before you click submit

To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit !

Click submit so we have your answers in our database!

Submit

Never submit passwords through Google Forms.

This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy.

